GSK plc GSK
NYSE GSK
$46.50 -0.02 (-0.04%)
At close: Oct 9, 2026 · 4:00 PM EDT

Gsk (GSK) Cash & Equivalents (2009 - 2026)

Updated

Gsk (GSK) posted Cash & Equivalents of $4.17 billion for the quarter ended Jun 30, 2026, down 13.2% from $4.8 billion a year earlier and down 10.2% from the prior quarter.

Analysis

Gsk (GSK) Cash & Equivalents (2009 - 2026) Analysis & Trends

As of Dec 31, 2025, Gsk's Cash & Equivalents came in at $4.48 billion, down 9.5% from the prior year.

  • Annual Cash & Equivalents shows a five-year compound annual growth rate of -11.1% (years ended Dec 2020 to Dec 2025).
  • In prior years, Gsk's Cash & Equivalents was $4.95 billion in the year ended Dec 31, 2024 (+35.5%), $3.65 billion in the year ended Dec 31, 2023 (-20.7%), $4.61 billion in the year ended Dec 31, 2022 (-21.6%) and $5.88 billion in the year ended Dec 31, 2021 (-27.2%).
  • The figure for the quarter ended Jun 30, 2026 stands as the lowest quarterly Cash & Equivalents since the quarter ended Sep 30, 2024.
  • On a year-over-year basis, Cash & Equivalents has declined in each of the last three quarters, with growth averaging 11.8% over the last eight quarters.
  • The strongest year-over-year quarter for Cash & Equivalents in the past five years was the quarter ended Mar 31, 2023, with growth of 585.3%; the weakest was the quarter ended Mar 31, 2022, with a decline of 92.2%.
  • According to Business Quant data, Cash & Equivalents for the three prior quarters was $4.64 billion (quarter ended Mar 31, 2026), $4.52 billion (quarter ended Dec 31, 2025) and $4.45 billion (quarter ended Sep 30, 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,109.58 Bn 1,078.16 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 630.16 Bn 548.69 Bn 17.26 Bn 20.42 Bn
3 AbbVie 488.57 Bn 461.73 Bn 12.70 Bn 6.57 Bn
4 Merck 359.15 Bn 313.58 Bn 12.21 Bn 6.85 Bn
5 Novartis Ag 274.32 Bn 238.71 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 246.73 Bn 220.50 Bn 12.86 Bn 4.89 Bn
7 Amgen 224.28 Bn 179.68 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 187.60 Bn 161.71 Bn 6.22 Bn 3.18 Bn
9 Pfizer 161.13 Bn 108.08 Bn 10.94 Bn 976.00 Mn
10 Gsk 100.33 Bn 81.91 Bn 8.24 Bn 4.17 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.17 Bn
Mar 31, 2026 4.64 Bn
Dec 31, 2025 4.52 Bn
Sep 30, 2025 4.45 Bn
Jun 30, 2025 4.80 Bn
Mar 31, 2025 5.62 Bn
Dec 31, 2024 4.97 Bn
Sep 30, 2024 4.15 Bn
Jun 30, 2024 3.74 Bn
Mar 31, 2024 3.54 Bn
Dec 31, 2023 3.64 Bn
Sep 30, 2023 4.02 Bn
Jun 30, 2023 3.93 Bn
Mar 31, 2023 3.51 Bn
Dec 31, 2022 4.37 Bn
Sep 30, 2022 4.25 Bn
Jun 30, 2022 8.14 Bn
Mar 31, 2022 512.58 Mn
Dec 31, 2021 5.76 Bn
Sep 30, 2021 4.76 Bn
API Access

Gsk Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=GSK&period=max&api_key=YOUR_API_KEY